Gilead's idelalisib shows promise against leukemia

10/9/2013 | Reuters

Gilead Sciences said a late-stage trial of its experimental drug idelalisib was halted early after a data-monitoring panel found that the drug significantly improved progression-free survival in patients with chronic lymphocytic leukemia who can't receive chemotherapy. Gilead said it is discussing the results of the study and a possible regulatory application with the FDA. In September, the firm submitted the drug for FDA approval as a treatment for non-Hodgkin lymphoma.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA